Imperial College London
Portrait Picture

ProfessorHolgerAuner

Faculty of Medicine, Department of Immunology and Inflammation

Visiting Professor
 
 
 
//

Contact

 

holger.auner04 Website

 
 
//

Assistant

 

Miss Mandy Sale +44 (0)20 3313 4017

 
//

Location

 

4N7ACommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Yong:2021:10.3324/haematol.2021.278399,
author = {Yong, KL and Hinsley, S and Auner, HW and Bygrave, C and Kaiser, MF and Ramasamy, K and De, Tute RM and Sherratt, D and Flanagan, L and Garg, M and Hawkins, S and Williams, C and Cavenagh, J and Rabin, NK and Croft, J and Morgan, G and Davies, F and Owen, RG and Brown, SR},
doi = {10.3324/haematol.2021.278399},
journal = {Haematologica: the hematology journal},
pages = {2694--2706},
title = {Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multi-centre, phase II, randomized, controlled trial (MUKfive)},
url = {http://dx.doi.org/10.3324/haematol.2021.278399},
volume = {106},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance. MUKfive was a phase II controlled, parallel group trial that randomised patients (2:1) to KCd (201) or VCd (99); responding patients on carfilzomib were randomised to maintenance carfilzomib (69) or no further treatment (72). Primary endpoints were (i) very good partial response (VGPR, non-inferiority, OR 0.8) at 24 weeks, and (ii) progression-free survival (PFS). More participants achieved ≥VGPR with carfilzomib compared to bortezomib (40.2% vs. 31.9%, OR=1.48, 90%CI:0.95,2.31; non-inferior), with a trend for particular benefit in adverse risk disease. KCd was associated with higher overall response (≥PR, 84.0% vs. 68.1%, OR=2.72, 90%CI:1.62,4.55, p=0.001). Neuropathy (grade ≥3 or ≥2 with pain) was more common with bortezomib (19.8% vs. 1.5%, p.
AU  - Yong,KL
AU  - Hinsley,S
AU  - Auner,HW
AU  - Bygrave,C
AU  - Kaiser,MF
AU  - Ramasamy,K
AU  - De,Tute RM
AU  - Sherratt,D
AU  - Flanagan,L
AU  - Garg,M
AU  - Hawkins,S
AU  - Williams,C
AU  - Cavenagh,J
AU  - Rabin,NK
AU  - Croft,J
AU  - Morgan,G
AU  - Davies,F
AU  - Owen,RG
AU  - Brown,SR
DO  - 10.3324/haematol.2021.278399
EP  - 2706
PY  - 2021///
SN  - 0390-6078
SP  - 2694
TI  - Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multi-centre, phase II, randomized, controlled trial (MUKfive)
T2  - Haematologica: the hematology journal
UR  - http://dx.doi.org/10.3324/haematol.2021.278399
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33910333
UR  - https://haematologica.org/article/view/haematol.2021.278399
UR  - http://hdl.handle.net/10044/1/88418
VL  - 106
ER  -
Download